Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2026)

Xenon Pharmaceuticals (XENE) has 6 years of Non Operating Income data on file, last reported at $7.5 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 8.17% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $27.5 million, a 26.58% decrease from a year earlier, with the FY2025 full-year figure at $28.2 million, down 31.07% from the prior year.
• Non Operating Income for Q1 2026 stood at $7.5 million, up from $5.0 million in the prior quarter.
• Over the last five years, Non Operating Income for XENE reached as high as $11.5 million in Q1 2024 and fell as low as -$2.7 million in Q1 2022.
• Historically, Non Operating Income has averaged $6.6 million across 5 years, with a median of $7.6 million in 2023.
• Across the five-year window, Non Operating Income soared 3023.55% in 2022 and slumped 42.11% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $7.1 million in 2022, then advanced by 23.63% to $8.7 million in 2023, then decreased by 9.18% to $7.9 million in 2024, then sank by 36.51% to $5.0 million in 2025, then jumped by 47.8% to $7.5 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $7.5 million in Q1 2026, $5.0 million in Q4 2025, and $6.1 million in Q3 2025.